摘要
Abstract
Objective To observe the effect of pioglitazone on gut-derived endotoxin in newly-diagnosed patients with type 2 diabetes and to analyze a possible new mechanism of improvement of insulin resistance by pioglitazone. Methods Ninety seven newly-diagnosed type 2 diabetic patients were divided randomly into pioglitazone group (n=49) and metformin group (n=48). The level of gut-derived endotoxin, high-sensitivity C-reactive protein (hs-CRP) , and other relative biochemical indicators were compared at baseline and after 12 weeks of treatment. Thirty gender- and age-matched healthy subjects served as controls. Results ① Levels of gut-derived endotoxin and hs-CRP were significantly higher in type 2 diabetic patients than in matched controls (P<0.01). ②Fasting plasma glucose (FPG), serum gut-derived endotoxin, hs-CRP and fasting insulin (FINS) were reduced significantly after pioglitazone treatment (P<0.05), in addition , there was a positive correlation between change in FINS level and change in gut-derived endotoxin level (r=0.475,P< 0.01). ③Although FPG and FINS also decreased after metformin treatment, the level of gut-derived endotoxin did not change significantly. ④In type 2 diabetic patients, gut-derived endotoxin was positively correlated with triglyceride, total cholesterol, FINS, hs-CRP, and homeostasis model assessment of insulin resistance (HOMA-IR) (P<0.05). When controlled for gender, age, and body mass index (BMI), HOMA-IR was an independent correlation factor of serum gut-derived endotoxin level. Conclusions Pioglitazone treatment could reduce gut-derived endotoxin in newly-diagnosed type 2 diabetic patients, which might be one of the factors playing a role in improving insulin resistance.关键词
吡格列酮/2型糖尿病/肠源性内毒素/胰岛素抵抗Key words
Pioglitazone/ Type 2 diabetes/ Gut-derived endotoxin/ Insulin resistance分类
医药卫生
